Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers

被引:87
作者
Muraoka, M [1 ]
Hu, ZP [1 ]
Shimokawa, T [1 ]
Sekino, S [1 ]
Kurogoshi, R [1 ]
Kuboi, Y [1 ]
Yoshikawa, Y [1 ]
Takada, K [1 ]
机构
[1] Kyoto Pharmaceut Univ, Dept Pharmaceut & Phamacokinet, Yamashina Ku, Kyoto 607, Japan
关键词
colon delivery; ethylcellulose; non-compartmental pharmacokinetic analysis; intestinal luminal pressure-controlled colon delivery capsule; colon luminal pressure;
D O I
10.1016/S0168-3659(97)00201-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The delivery ability of a pressure-controlled colon delivery capsule (PCDC) containing caffeine as a test drug was evaluated after oral administration to healthy male human volunteers. The driving force causing PCDC disintegration in the intestinal tract is the physiological luminal pressure which results from peristalsis. Three kinds of PCDCs having different thickness of a water-insoluble polymer membrane were prepared by coating the inner surface of the gelatin capsules with ethylcellulose (EC). The mean thicknesses were 40+/-1 (S,E.) for type 1, 44+/-1 for type 2 and 50+/-1 mu m for type 3 PCDC, respectively. Caffeine was dissolved with a suppository base (PEGs 400 and 1000) and the capsules were filled. Doses were 15, 45 or 75 mg. After blank saliva samples were obtained, test preparations were orally administered to the volunteers and saliva samples were collected for 1 min intervals hourly from 1 to 10 h in the fasted state study, and from 1 to 20 h and at 25 h in the fed state study. Caffeine concentrations in the saliva samples were analyzed by HPLC. The maximum salivary caffeine excretion rate increased as the oral caffeine dose increased. The maximum salivary caffeine excretion rate increased predominantly compared to the pre-dose level in 75 mg dose study. Therefore, all following studies were performed with this dose. The first appearance time of caffeine into the saliva, T-i was used as a parameter to estimate the disintegration time of test preparations in the gastrointestinal tract. The mean T-i of types 1, 2, and 3 PCDCs were 3.0+/-0.4, 4.0+/-0.4 and 4.5+/-0.3 h, respectively. After oral administration of 75 mg caffeine in plain gelatin capsule as a reference preparation, caffeine appeared in the saliva within 0.5 h. The mean hardness of the PCDCs were 1.05+/-0.10 (type 1), 1.55+/-0.06 (type 2) and 2.08+/-0.15 newton (type 3), respectively. There were good correlations between three parameters: EC coating membrane thickness, hardness and T-i (determination coefficient r(2)=0.935 between T-i and thickness, r(2)=0.998 between thickness and hardness, r(2)=0.958 between hardness and T-i). The effect of food intake on the delivery ability was examined with type 3 PCDCs. Food intake prolonged the mean T-i from 4.5+/-0.3 to 7.8+/-1.3 h, This increase is thought to be ascribed to prolonged gastric emptying time. Comparison with reported colon arrival times indicates that the type 3 PCDC functions in colon delivery of caffeine and is thought to be applicable to other drugs. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:119 / 129
页数:11
相关论文
共 43 条
[31]   A NEW APPROACH TO THE ORAL-ADMINISTRATION OF INSULIN AND OTHER PEPTIDE DRUGS [J].
SAFFRAN, M ;
KUMAR, GS ;
SAVARIAR, C ;
BURNHAM, JC ;
WILLIAMS, F ;
NECKERS, DC .
SCIENCE, 1986, 233 (4768) :1081-1084
[32]  
STEPHEN HB, 1996, DRUG THER, V334, P841
[33]   Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs [J].
Takaya, T ;
Sawada, K ;
Suzuki, H ;
Funaoka, A ;
Matsuda, K ;
Takada, K .
JOURNAL OF DRUG TARGETING, 1997, 4 (05) :271-276
[34]   DEVELOPMENT OF A COLON DELIVERY CAPSULE AND THE PHARMACOLOGICAL ACTIVITY OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR (RHG-CSF) IN BEAGLE DOGS [J].
TAKAYA, T ;
IKEDA, C ;
IMAGAWA, N ;
NIWA, K ;
TAKADA, K .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (06) :474-478
[35]   SIMULTANEOUS DETERMINATION OF CAFFEINE AND ITS PRIMARY DEMETHYLATED METABOLITES IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
TANAKA, E .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 575 (02) :311-314
[36]  
TANGLIU DD, 1983, J PHARMACOL EXP THER, V224, P180
[37]   In vitro evaluation of pectin-based colonic drug delivery systems [J].
Wakerly, Z ;
Fell, JT ;
Attwood, D ;
Parkins, DA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 129 (1-2) :73-77
[38]   THE ROLE OF GASTRIC-EMPTYING IN THE ABSORPTION AND METABOLISM OF NIFEDIPINE GIVEN IN A MODIFIED RELEASE PELLET FORMULATION [J].
WILDING, IR ;
SPARROW, RA ;
DAVIS, SS ;
HORTON, RJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 84 (01) :59-67
[39]  
WOODLEY JF, 1994, CRIT REV THER DRUG, V11, P61
[40]  
YOSHIKAWA Y, 1995, INT J BIOMED COMPUT, V47, P474